IDEXX Laboratories (IDXX) has collected significant attention in recent times with its stock performance. Over the last year, the stock has rallied 43%-71%, a surge largely driven by strategic investments, new product launches, favorable financial results and the growing pet aging market.
Mirae Asset Global Investments and
Sumitomo Mitsui Trust Group have considerably increased their shares in IDEXX, while
Robeco Institutional Asset Management and
Rathbones Group reduced theirs. Interestingly, IDEXX has also unveiled its
canine cancer detection panel in the UK, a significant catalyst that could potentially shift the preventive care narrative. Despite concerns about leadership transition, the company's continuous innovation and increased 2026 outlook is evident. Multiple brokerages, including
Citigroup, value the stock with a \"Moderate Buy\" to \"Buy\" rating, depending on underlying strengths. The company recently beat Q4 earnings and revenue estimates, but saw its stock down 3.7%, reflecting market volatility. Meanwhile,
Fidelity Growth Strategies Fund has chosen to avoid IDEXX due to questionable growth durability.
Idexx Laboratories IDXX News Analytics from Mon, 04 Aug 2025 07:00:00 GMT to Sat, 18 Apr 2026 10:40:53 GMT -
Rating 7
- Innovation 8
- Information 5
- Rumor 8
